La Grande Observer

Breakthrough! Exciting interim Phase II Data of LP-003 in CSU released by Longbio at AAAAI 2025

SAN DIEGO, March 2, 2025 /PRNewswire/ — Longbio Pharma (Suzhou) Co., Ltd. (referred to as “Longbio”), a leading biotech company dedicated to developing innovative biologic treatments for allergy, ...
Nasdaq

Lipella Pharmaceuticals Inc. Reports Positive Topline Results from Phase 2a Trial of LP-310 for Oral Lichen Planus

Lipella Pharmaceuticals Inc. announced positive topline results from the second cohort of its Phase 2a clinical study of LP-310, a liposomal-tacrolimus oral rinse aimed at treating oral lichen planus ...
manilatimes

Superior Efficacy and Long-acting: LongBio Announces Positive Topline Results from Phase II CSU Trial of Next-Generation Anti-IgE Therapy, LP-003 in Head-to-Head Comparison ...

PHILADELPHIA, March 2, 2026 /PRNewswire/ -- LongBio Pharma (Suzhou) Co., Ltd. ("LongBio"), a clinical-stage biotech company focused on discovery and development of biologics targeting allergic and ...
Seeking Alpha

Lantern Pharma Reports Additional Positive LP-184 Phase 1a Results Showing Durable Disease Control in Heavily Pre-Treated Advanced Cancer Patients as Company Advances Precision ...

DALLAS--(BUSINESS WIRE)-- Lantern Pharma Inc. (LTRN), a clinical-stage biotechnology company using artificial intelligence and genomics to transform oncology drug development, announced additional ...